Business Context and Reporting Period
This Form 8-K is filed by Helius Medical Technologies, Inc. (not Solana Co) on April 30, 2025. The report details a material modification to the rights of security holders regarding a reverse stock split approved by stockholders on April 21, 2025, and filed with the Delaware Secretary of State on April 30, 2025.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. The only quantitative data relates to capital structure adjustments:
- Outstanding Shares (Pre-Split): 7,920,928
- Outstanding Shares (Post-Split): Approximately 0.5 million
- Authorized Shares: 150 million (unchanged)
- Par Value: $0.001 (unchanged)
Material Changes
The primary material change is the implementation of a 1-for-15 reverse stock split effective May 1, 2025, at 5:00 p.m. Eastern Time. This action was taken to enable the Company to comply with Nasdaq Stock Market continued listing requirements. Key operational changes include:
- Every 15 shares of issued and outstanding Common Stock will be combined into 1 share.
- Trading on a split-adjusted basis is expected to begin on May 2, 2025.
- The new CUSIP number will be 42328V 884.
- Proportionate adjustments will be made to exercise prices and share counts for outstanding options, RSUs, and warrants.
Guidance, Outlook, and Risks
The filing does not contain forward-looking financial guidance or management commentary on future performance. The stated purpose of the reverse split is regulatory compliance with Nasdaq listing standards. Regarding fractional shares, the Company reserves the right to either round down and pay cash for the fractional value or round up to the next whole share.
Investor Verification Checklist
- Verify the effective date of the reverse split (May 1, 2025) and the resumption of trading (May 2, 2025).
- Confirm the new CUSIP number (42328V 884) for trading and settlement purposes.
- Review the treatment of fractional shares (cash payment vs. rounding up) as determined by the Company.
- Check the adjustment of exercise prices and share quantities for any held stock options or warrants.
- Confirm the Company's continued compliance with Nasdaq listing requirements post-split.